SPEXIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0588 CHF | +15.29% |
|
+2.08% | +43.41% |
| 01/05 | SIX Swiss Exchange Approves Delay in Spexis' FY23 Annual Report Publication | MT |
| 17/04 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 4.34M | - | - | - | - | - | |
| 86.85B | ||||||
| 40.16B | ||||||
| 31.28B | ||||||
| 25.27B | ||||||
| 15.33B |
- Stock Market
- Equities
- POLN Stock
- Charts Spexis AG
- Sector Chart
